08:52 AM EDT, 10/06/2025 (MT Newswires) -- MaxCyte ( MXCT ) said Monday it has entered a strategic platform license agreement with Moonlight Bio, a Seattle-based preclinical biotech firm.

The company said Moonlight Bio will use its Flow Electroporation technology and ExPERT platform to advance its T cell therapy programs.

The agreement grants Moonlight Bio non-exclusive rights for research, clinical, and commercial use, the company added.

MaxCyte ( MXCT ) said it will receive annual licensing fees and program-related revenue as part of the agreement.

Shares of MaxCyte ( MXCT ) were up 5.9% in Monday's premarket activity.